ebook: High-content analysis and infectious disease
Learn how you could use high-content analysis for functional & phenotypic assays in your infectious disease research or drug discovery.
List view / Grid view
Medical screening is a strategy used to identify the possible presence of an as-yet-undiagnosed disease in individuals without signs or symptoms.
Learn how you could use high-content analysis for functional & phenotypic assays in your infectious disease research or drug discovery.
Bioassays and thin-layer chromatography has been used by scientists to analyse molecules in plant extracts as a fast and cost-effective method for identifying new drug compounds.
7 May 2020 | By PerkinElmer
High-throughput screening (HTS) cascades have evolved to ensure that high quality hits can be identified from large screening collections.
David Johnson of GigaGen discusses how recombinant forms of intravenous immunoglobulins (IVIG) could overtake current IVIG therapies and be used in the treatment of COVID-19.
A series of three new assays to screen for drug compounds or proteins that combat the COVID-19 coronavirus has been developed.
Bringing together protein science, drug discovery experience and innovative technology, a new collaboration aims to identify novel drug targets for COVID-19.
A new study has revealed that less than 10 percent of respiratory and intestinal cells are susceptible to SARS-CoV-2 infection and expression of ACE2 receptors is driven by the body's immune response.
The developers of a novel method to create immunological assay probes for screening T cells has leveraged their new protocol against COVID-19.
High-throughput screening of thousands of compounds has revealed several candidates, including lead compound ebselen, with the potential for treating COVID-19.
A collaboration between academia and industry has produced an assay and new screening technique which utilises directed evolution for the discovery of antibody-based drugs.
There are heightened levels of abnormal stem cells in the lungs of COPD patients, presenting a drug target that researchers are screening compounds against.
After screening 300 antibodies, Celltrion has identified the 14 most powerful that could potentially combat the COVID-19 coronavirus.
Chinese researchers who determined the crystal structure of the COVID-19 protease Mpro used this information to screen over 10,000 compounds to combat the coronavirus.
Drug Target Review discusses how NETSseq, a novel profiling technology, is bringing new insights to neurodegenerative and psychiatric diseases.
ESHG 2019 Conference Presentation: Using KingFisher™ to increase reproducibility in new applications using challenging samples.